Pelthos Therapeutics Inc.
PTHS
$36.31
$1.564.49%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 3,860.00% | -58.36% | -213.53% | 744.40% | -74.00% |
| Gross Profit | -3,860.00% | 58.36% | 213.53% | -744.40% | 74.00% |
| SG&A Expenses | 55.08% | 11.74% | -2.83% | 31.47% | 140.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.12% | -5.17% | -52.95% | 58.57% | 126.98% |
| Operating Income | -83.12% | 5.17% | 52.95% | -58.57% | -126.98% |
| Income Before Tax | -94.68% | 23.21% | 52.30% | -19.20% | -85.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.68% | 23.21% | 52.30% | -19.20% | -85.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.68% | 23.21% | 52.30% | -19.20% | -85.84% |
| EBIT | -83.12% | 5.17% | 52.95% | -58.57% | -126.98% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -75.49% | 41.22% | 84.12% | 79.74% | 67.72% |
| Normalized Basic EPS | -75.48% | 41.22% | 84.12% | 75.40% | 67.72% |
| EPS Diluted | -75.49% | 41.22% | 84.12% | 79.74% | 67.72% |
| Normalized Diluted EPS | -75.48% | 41.22% | 84.12% | 75.40% | 67.72% |
| Average Basic Shares Outstanding | 10.93% | 30.63% | 200.50% | 488.02% | 475.67% |
| Average Diluted Shares Outstanding | 10.93% | 30.63% | 200.50% | 488.02% | 475.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |